Biliary Tract Cancer (BTC) Market across the 7MM reached approximately USD 1 billion in 2023

The global Biliary Tract Cancer (BTC) market across the 7MM reached approximately USD 1 billion in 2023 and is projected to grow steadily through 2034, driven by rising disease burden and the introduction of innovative targeted and immunotherapies.

Biliary Tract Cancer Market Summary

In 2023, the United States dominated the BTC market, capturing nearly 48% of the total 7MM market share, followed by Italy with the highest share in the EU region and Spain with the lowest. Japan recorded the highest incident cases, reflecting its growing clinical burden.

In the U.S., the highest prevalence was observed among individuals aged 70–79 years (~30%). Clinical symptoms vary based on tumor site - extrahepatic tumors frequently present with painless jaundice, while intrahepatic tumors commonly cause abdominal pain along with pruritus, fatigue, and fever.

Diagnosis typically relies on ultrasound, CT, MRI, and confirmatory biopsy. Treatment strategies differ by disease stage:

• Early-stage: surgical resection followed by adjuvant chemotherapy
• Locally advanced disease: loco-regional therapies
• Advanced/metastatic disease: gemcitabine + cisplatin remains first-line

Although chemotherapy remains the backbone of management, the field is rapidly evolving with novel agents. Targeted therapies such as FGFR2 inhibitors (PEMAZYRE, LYTGOBI), immunotherapies like KEYTRUDA (expanded approval in 2023), and precision medicines including TAFINLAR + MEKINIST, ROZLYTREK, and VITRAKVI are reshaping outcomes. However, survival rates remain low due to late-stage diagnosis and aggressive disease biology.

DelveInsight’s latest report, “Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast – 2034,” offers an in-depth assessment of historical epidemiology, market trends, pipeline advancements, and competitive dynamics across the US, EU5, and Japan. It further outlines treatment algorithms, unmet needs, and future market opportunities.

Download the sample report to explore evolving epidemiology, treatment pathways, and the future of BTC care.

Key Highlights from the Biliary Tract Cancer Market Report

• The BTC market in the 7MM is anticipated to grow at a notable CAGR through 2034.
• The US accounted for nearly half of the market share in 2023.
• Leading companies operating in the BTC space include Basilea Pharmaceutica, Zymeworks, BeiGene, Incyte, Bayer, Roche, QED Therapeutics, Agios, Merck, AstraZeneca, Taiho Oncology, Eisai, Delcath Systems, and several others.
• Important emerging therapies expected to enter the market include PEMAZYRE, IMFINZI, CTX-009, Zanidatamab, and additional targeted agents.

Recent Regulatory Milestones in Biliary Tract Cancer Pipeline

• July 2025: The FDA granted Orphan Drug Designation to FUJIFILM’s FF-10832, a liposomal gemcitabine formulation for BTC, currently in Phase 2a evaluation.
• July 2025: The European Commission issued conditional approval for Ziihera® (zanidatamab) for previously treated HER2-positive BTC.
• Nov 2024: The FDA granted accelerated approval for zanidatamab-hrii for HER2-positive BTC.
• Nov 2024: The FDA approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) test for BTC diagnostics.
• 2024 Clinical Highlights: Genome & Company and AstraZeneca released positive data from BTC trials involving GEN-001 + pembrolizumab and durvalumab with gemcitabine-based chemotherapy, respectively.
• 2023: Jazz Pharmaceuticals and Zymeworks executed a strategic acquisition agreement to transfer zanidatamab development assets to Jazz.

Biliary Tract Cancer Overview

Biliary Tract Cancer is a rare but highly aggressive malignancy originating from the epithelial lining of the biliary tree, including the intrahepatic ducts, extrahepatic ducts, and the gallbladder. Based on anatomical origin, BTC is categorized into:

• Intrahepatic cholangiocarcinoma
• Extrahepatic cholangiocarcinoma
• Gallbladder cancer

Symptoms depend largely on tumor site, with extrahepatic tumors typically causing obstructive jaundice and intrahepatic tumors presenting with abdominal pain and systemic symptoms like fatigue and weight loss.

Diagnosis involves physical examination, imaging, and biopsy, though many cases are identified at advanced stages. Treatment varies by stage - ranging from surgical resection to loco-regional therapies and systemic chemotherapy. Targeted therapies and immunotherapies are increasingly being integrated into treatment pathways.

Biliary Tract Cancer Market Outlook

The BTC market is set for significant expansion between 2024–2034, driven by new approvals, improved diagnostics, and rising awareness. In 2023, the total 7MM market size was roughly USD 1 billion, with the US contributing the largest share, followed by Japan.

By 2034, chemotherapy regimens are expected to generate ~USD 360 million in the US alone.

Key Approved Therapies Transforming Care

• IMFINZI (durvalumab) – First-line (approved Sept 2022)
• KEYTRUDA (pembrolizumab) – First-line (approved Nov 2023)
• LYTGOBI (futibatinib) – FGFR2 inhibitor
• PEMAZYRE (pemigatinib) – FGFR2 inhibitor
• ROZLYTREK, TIBSOVO, TAFINLAR + MEKINIST – Targeted options for select molecular subsets

Promising Late-Stage Biliary Tract Cancer Pipeline Therapies

• Tinengotinib (TransThera Sciences)
• Rilvegostomig (AstraZeneca/Compugen)
• Zanidatamab (Jazz/Zymeworks)
• CTx-009 (Compass Therapeutics)
• CX-4945

These advancements are expected to significantly shift the BTC treatment paradigm over the next decade.

Biliary Tract Cancer Market Drivers

• Increasing incidence and rising aging population
• Advances in molecular diagnostics and biomarker profiling
• Robust growth in targeted and immunotherapy development
• Strong late-stage R&D pipeline
• Rising healthcare expenditure and adoption of advanced oncology treatments

Biliary Tract Cancer Market Barriers

• High cost of novel therapies
• Late-stage diagnosis limiting surgical intervention
• Tumor heterogeneity affecting treatment response
• Resistance mechanisms and treatment toxicity
• Reimbursement and regulatory hurdles

Biliary Tract Cancer Epidemiology

In 2023, the United States reported the highest share of biliary tract cancer incidence in the 7MM, contributing approximately 30% of total cases. TP53 mutations were the most common among mutation-specific cases in the US, followed by KRAS mutations. Within the EU4 and the UK, Italy recorded the highest number of cases, followed by Germany, while Spain reported the fewest. In Japan, Stage IV disease represented the largest portion of stage-specific cases in 2023, and these numbers are expected to rise by 2034.

 

Biliary Tract Cancer Epidemiology Segmentation:

• Incident cases across the 7MM
• Age-wise and stage-wise distribution
• Tumor-location specific epidemiology
• Mutation-positive patient segments
• Treated patient population and therapeutic eligibility trends

Biliary Tract Cancer Pipeline Spotlight

CTX-009 (Compass Therapeutics)

A bispecific antibody inhibiting DLL4/Notch and VEGF-A, showing strong antitumor activity across multiple solid tumors. Currently in Phase III for BTC.

Zanidatamab (Jazz/Zymeworks)

A next-generation HER2-targeted agent with multiple regulatory designations (Breakthrough, Fast Track, Orphan Drug). Pivotal trials are underway for HER2-positive BTC.

About DelveInsight

DelveInsight is a trusted provider of Life Sciences market intelligence, delivering high-quality syndicated reports and bespoke consulting solutions to support strategic decision-making across biopharma and healthcare.